KCT0005495进行中（未招募）未知
A study for identification of immune determinants for response to nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Sex: Male or female
- •2. Age (at the time of informed consent): 18 years and older
- •3. Subjects with histologically- or cytologically-confirmed recurrent and/or metastatic head and neck squamous cell carcinoma (Recurrent/Metastatic HNSCC)
- •4. Known human papilloma virus (HPV) infection status with p16 immunohistochemistry or HPV in-situ hybridization
- •5. Failed or intolerable to previous platinum-based chemotherapy
- •6. Patients who have at least 1 measurable or non-measurable lesion per the RECIST (Response Evaluation Criteria in Solid Tumor) Guideline Ver. 1.1 as confirmed by imaging within 28 days before enrollment. The following requirements should also be satisfied:
- •- If patients only have lesions that were previously treated with radiation, the lesion should be limited to one with confirmed aggravation by imaging after radiation.
- •- If patients have pericardial or pleural effusion or ascites only, the lesion should be limited to one with cytologically confirmed malignancy.
- •7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- •8. Patients with a life expectancy of at least 3 months
- •9. Screening laboratory values within the specified ranges stated below, obtained within 14 days prior to first dose:
- •- White blood cells =2,000/mm3 and neutrophils =1,500/mm3
- •- Platelets =100,000/mm3
- •- Hemoglobin =9.0 g/dL
- •- AST (GOT) and ALT (GPT) =3.0-fold the upper limit of normal (ULN) of the study site (or =5.0-fold the ULN of the study site in patients with liver metastases)
- •- Total bilirubin =1.5-fold the ULN of the study site
- •- Creatinine =1.5-fold the ULN of the study site or creatinine clearance (either the measured or estimated value using the Cockcroft-Gault equation) >45 mL/min
- •10. Explicit and voluntary consent to participate in the study obtained using a signed and dated informed consent form clearly and fully describing the purpose, potential risks, and any other critical issues regarding the study
- •11. Women of childbearing potential (including women with chemical menopause or no menstruation for other medical reasons#1) must agree to use contraception(#2) from the time of informed consent until 5 months or more after the last dose of the investigational product. Also, women must agree not to breastfeed from the time of informed consent until 5 months or more after the last dose of the investigational product
- •12. Men must agree to use contraception(#2) from the start of study treatment until 7 months or more after the last dose of the investigational product.
- •- #1 Women of childbearing potential are defined as all women after the onset of menstruation who are not postmenopausal and have not been surgically sterilized (e.g., hysterectomy, bilateral tubal ligation, bilateral oophorectomy). Postmenopause is defined as amenorrhea for =12 consecutive months without specific reasons. Women using oral contraceptives, intrauterine devices, or mechanical contraception such as contraceptive barriers are regarded as having childbearing potential.
- •- #2 The subject must consent to use any two of the following methods of contraception: vasectomy or condom for patients who are male or female subject’s partner and tubal ligation, contraceptive diaphragm, intrauterine device, spermicide, or oral contraceptive for patients who are female or male subject’s partner.
排除标准
- •1. Patients with multiple primary cancers (with the exception of completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer, or any other cancer that has not recurred for at least 3 years)
- •2. Patients with residual adverse effects of prior therapy or effects of surgery that would affect the safety evaluation of the investigational product in the opinion of the investigator or sub-investigator.
- •3. Patients with current or past history of severe hypersensitivity to any other antibody products
- •4. Patients with concurrent autoimmune disease or history of chronic or recurrent autoimmune disease
- •5. Patients with a current or past history of interstitial lung disease or pulmonary fibrosis diagnosed based on imaging or clinical findings. Patients with radiation pneumonitis may be enrolled if the radiation pneumonitis has been confirmed as stable (beyond acute phase) without any concerns about recurrence.
- •6. Patients with concurrent diverticulitis or symptomatic gastrointestinal ulcerative disease
- •7. Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment. Patients may be enrolled if
- •the metastasis is asymptomatic and requires no treatment.
- •8. Patients with pericardial fluid, pleural effusion, or ascites requiring treatment
- •9. Patients with uncontrollable, tumor-related pain
- •10. Patients who have experienced medically refractory transient ischemic attack, cerebrovascular accident, thrombosis, or thromboembolism (pulmonary arterial embolism or deep vein thrombosis) within 180 days before enrollment
- •11. Patients with a history of uncontrollable or significant cardiovascular disease meeting any of the following criteria:
- •-Myocardial infarction within 180 days before enrollment
- •?-Uncontrollable angina pectoris within 180 days before enrollment
- •?-New York Heart Association (NYHA) Class III or IV congestive heart failure
- •?-Uncontrollable hypertension despite appropriate treatment (e.g., systolic blood pressure =150 mmHg or
- •diastolic blood pressure = 90 mmHg lasting 24 hours or more)
- •?-Arrhythmia requiring treatment
- •12. Patients with uncontrollable diabetes mellitus
- •13. Patients with systemic infections requiring treatment with intravenous antibiotics
- •14. Patients who have received systemic corticosteroids (more than 10mg/day prednisolone except for temporary use, e.g., for examination or prophylaxis of allergic reactions) or immunosuppressants within 28 days before enrollment
- •15. Patients who have received antineoplastic drugs (e.g., chemotherapy agents, molecular-targeted therapy agents, or immunotherapy agents) within 14 days before enrollment
- •16. Patients who have undergone surgical adhesion of the pleura or pericardium within 14 days before enrollment
- •17. Patients who have undergone surgery under general anesthesia within 14 days before enrollment
- •18. Patients who have undergone surgery involving local or topical anesthesia within 7 days before enrollment
- •19. Patients who have received radiotherapy within 14 days before enrollment, or radiotherapy to bone metastases within
- •7 days before enrollment
- •20. Patients who have received any radiopharmaceuticals
- •(except for examination or diagnostic use of radiopharmaceuticals) within 56 days before enrollment
- •21. Patients with a positive test result for any of the following: HIV-1 antibody, HIV-2 antibody, HTLV-1 antibody,
研究者
相似试验
招募中
不适用
Detection of markers for immune pathophysiology and analysis of their prognostic value in patients with chronic thrombocytopenia without an increase in the number of bone marrow megakaryocytes: a prospective observation study.Pancytopenia, thrombocytopeniaJPRN-UMIN000002729Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science.50
已完成
不适用
Study of immune parameters that may differ between HC and patients with MS : an explorative studyMS1000381610007951Multiple SclerosisNL-OMON37483School for Mental Health and Neuroscience100
尚未招募
不适用
Investigation of biomarkers to predict immune-related adverse events in patients with non-small cell lung canceron-small cell lung cancerJPRN-UMIN000047162Kobe University114
招募中
不适用
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic TumorsSolid Tumor, AdultSolid Tumor, ChildhoodHematologic CancerNCT05481502Gustave Roussy, Cancer Campus, Grand Paris160
Unknown
2 期
Biomarkers in Urothelial Cancer Patients Treated With PembrolizumabTransitional Cell Carcinoma of the BladderBiomarkersNCT03263039Erasmus Medical Center80